Teva Pharmaceutical Industries Limited
TEVA
$26.88
$0.160.60%
NYSE
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.78B | 16.63B | 16.62B | 16.54B | 16.77B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.78B | 16.63B | 16.62B | 16.54B | 16.77B |
| Cost of Revenue | 8.37B | 8.38B | 8.45B | 8.48B | 8.41B |
| Gross Profit | 8.40B | 8.25B | 8.17B | 8.06B | 8.36B |
| SG&A Expenses | 3.80B | 3.75B | 3.73B | 3.70B | 3.65B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 44.00M | 16.00M | 10.00M | -9.00M | -1.00M |
| Total Operating Expenses | 13.21B | 13.13B | 13.19B | 13.17B | 13.04B |
| Operating Income | 3.56B | 3.50B | 3.42B | 3.37B | 3.73B |
| Income Before Tax | 899.00M | -70.00M | -519.00M | -1.28B | -529.00M |
| Income Tax Expenses | 238.00M | 93.00M | 801.00M | 675.00M | 688.00M |
| Earnings from Continuing Operations | 661.00 | -163.00 | -1.32K | -1.96K | -1.22K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 51.00M | 5.00M | 34.00M | 320.00M | 258.00M |
| Net Income | 712.00M | -158.00M | -1.29B | -1.64B | -959.00M |
| EBIT | 3.56B | 3.50B | 3.42B | 3.37B | 3.73B |
| EBITDA | 4.58B | 4.52B | 4.45B | 4.43B | 4.79B |
| EPS Basic | 0.62 | -0.14 | -1.14 | -1.45 | -0.84 |
| Normalized Basic EPS | 1.49 | 1.40 | 1.39 | 1.61 | 1.74 |
| EPS Diluted | 0.60 | -0.16 | -1.15 | -1.46 | -0.86 |
| Normalized Diluted EPS | 1.47 | 1.39 | 1.38 | 1.61 | 1.73 |
| Average Basic Shares Outstanding | 4.57B | 4.55B | 4.54B | 4.52B | 4.51B |
| Average Diluted Shares Outstanding | 4.62B | 4.59B | 4.56B | 4.52B | 4.53B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |